Skip to content
Review Open access

IUC26589-95 First-Line or Maintenance Immune Checkpoint Inhibitors in Older Patients with Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis

Aug 2026 · The Oncologist · Vol 31 · 0 citations

TL;DR

In clinically fit older patients, combination-based first-line and maintenance treatment was associated with improved OS and PFS, and these findings argue against routine de-escalation strategies on the basis of age alone.

Abstract

Abstract Background Evidence on immune-based treatment in older patients with advanced urothelial carcinoma are limited because age-specific outcomes are usually exploratory. We assessed the efficacy of first-line and maintenance immune-based strategies in patients aged ≥65 years. Methods PubMed/MEDLINE, Embase, Cochrane and major oncology congresses were searched from Jan 2015 to May 2026 for randomized trials reporting age-specific hazard ratios (HRs) for overall survival (OS) or progression-free survival (PFS). The primary analysis pooled first-line combination regimens versus platinum-based chemotherapy using random-effects models. For maintenance treatment, an anchored Bucher indirect comparison used avelumab as the shared treatment node, evaluating PFS as the primary endpoint. Results Six first-line randomized trials of first-line treatment combination were identified. A number of 2,678 patients aged ≥65 years were represented in experimental and control groups. All first-line estimates came from exploratory age subgroup analyses. Combination first-line regimens improved OS versus chemotherapy (HR 0.79, 95% CI 0.64–0.96), although heterogeneity was substantial (I² = 69.8%; p  =  0.0029). Pooled estimates were HR 0.56 (95% CI 0.26–1.20) for antibody-drug conjugate plus immunotherapy (ADC+IO), HR 0.86 (95% CI 0.64–1.14) for ICI plus chemotherapy, and HR 0.91 (95% CI 0.35–2.38) for dual ICI combinations. Treatment effects differed across categories (p < 0.0001), but comparisons were confounded by differences in population selection, cisplatin eligibility, and trial design. ICI monotherapy did not show an OS benefit: pembrolizumab versus chemotherapy yielded HR 1.15 (95% CI 0.84–1.59), while the atezolizumab estimate was HR 0.98 (95% CI 0.79–1.21). In maintenance, avelumab improved PFS versus best supportive care (HR 0.46, 95% CI 0.37–0.57). The indirect comparison estimated an HR of 0.31 (95% CI 0.18–0.54; p < 0.0001) for avelumab plus sacituzumab govitecan versus best supportive care. Conclusions In clinically fit older patients, combination-based first-line and maintenance treatment was associated with improved OS and PFS. In contrast, the available data did not show a survival benefit with ICI monotherapy. These findings argue against routine de-escalation strategies on the basis of age alone. Further age-specific efficacy, safety, and geriatric assessment data are needed to guide treatment selection.IUC26589-95  Figure 1 Pooled OS HR for fist-line treatment combinations

Read PDF

Similar papers

Review Open access Dec 2024

Addition of immune checkpoint inhibitor to standard of care chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis

Background: Preliminary findings from this study were previously published as a conference abstract (https://doi.org/10.1158/2326-6074.IO2025-B039). Immune checkpoint inhibitors (ICIs) have shown activity in nasopharyngeal carcinoma (NPC), but their efficacy and safety when integrated with standard chemoradiotherapy (C...

R. Srinivasmurthy, J. Ta, S. Afifi et al. · 3 citations
Review Open access Sep 2026

First-line immune checkpoint inhibitors combined with targeted therapy for advanced renal cell carcinoma: a network meta-analysis and cost-effectiveness analysis

Objective This study aimed to systematically evaluate the efficacy of first-line immune checkpoint inhibitors (ICIs) combined with targeted therapy for advanced renal cell carcinoma (RCC) and assess their cost-effectiveness from the perspective of the Chinese healthcare system. Methods Phase III randomized controlled t...

Yi-Ze Jia, Shan Zhao, Xiao-Hui Wang et al. · 0 citations
Review Nov 2026

Comparative efficacy and safety of first-line therapies for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.

BACKGROUND First-line regimens incorporating immune checkpoint inhibitors (ICIs), adoptive cell therapy (ACT), and targeted agents have expanded treatment options for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma, but their comparative efficacy and safety remain uncertain. METHODS We sear...

Wen-Wei Yang, Qi Cao, B. Cao et al. · 0 citations
Open access Oct 2026

Real-world effectiveness of first-line chemoimmunotherapy versus chemotherapy in older adults with extensive-stage small cell lung cancer: an inverse probability treatment weighted analysis.

Comparison evidence of improved survival in association with ICI-chemo compared with chemo in older adults with ES-SCLC is provided, providing comparative evidence of improved survival in association with ICI-chemo.

Si-Yuan Cui, Kui Zhao, Na Wang et al. · 0 citations
Review Open access Oct 2026

Immune checkpoint inhibitor‑based vs. non‑immunotherapy subsequent treatment after progression on first‑line chemoimmunotherapy in extensive‑stage small cell lung cancer: A meta‑analysis

. First‑line chemoimmunotherapy is currently a standard treatment for extensive‑stage small cell lung cancer (ES‑SCLC), but the value of immune checkpoint inhibitor (ICI)‑based subsequent treatment after progression remains uncertain. The present meta‑analysis assessed the efficacy and safety of ICI‑based vs. non‑immun...

Chuan Long, Ying-Ding Ruan, Ai-Ming Yang et al. · 0 citations
Review Open access Sep 2026

Pembrolizumab plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: 4.5-year follow-up from the randomized phase III KEYNOTE-859 study

Extended follow-up confirms that first-line pembrolizumab plus chemotherapy improves efficacy and maintains a manageable safety profile compared with placebo plus chemotherapy, regardless of PD-L1 status, supporting this combination as a first-line treatment option for locally advanced or metastatic HER2-negative gastr...

S. Rha, L. Wyrwicz, P. Yanez et al. · 1 citation · ⚡1

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.